<?xml version="1.0" ?>
<document id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3">
  <chunk id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c0" text="Lysosomotropic agents as HCV entry inhibitors">
    <entity charOffset="35-45" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c0.e0" ontology_id="CHEBI_35222" text="inhibitors" type="chemical"/>
  </chunk>
  <chunk id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1" text="HCV has two envelop proteins named as E1 and E2 which play an important role in cell entry through two main pathways: direct fusion at the plasma membrane and receptor-mediated endocytosis. Fusion of the HCV envelope proteins is triggered by low pH within the endosome. Lysosomotropic agents (LA) such as Chloroquine and Ammonium chloride (NH 4 Cl) are the weak bases and penetrate in lysosome as protonated form and increase the intracellular pH. To investigate the antiviral effect of LA (Chloroquine and NH 4 Cl) on pH dependent endocytosis, HCV pseudoparticles (HCVpp) of 1a and 3a genotype were produced and used to infect liver cells. The toxicological effects of Chloroquine and NH 4 Cl were tested in liver cells through MTT cell proliferation assay. For antiviral screening of Chloroquine and NH 4 Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer. The results demonstrated that Chloroquine and NH 4 Cl showed more than 50% reduction of virus infectivity at 50 Î¼M and 10 mM concentrations respectively. These results suggest that inhibition of HCV at fusion step by increasing the lysosomal pH will be better option to treat chronic HCV.">
    <entity charOffset="20-28" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e0" ontology_id="CHEBI_36080" text="proteins" type="chemical"/>
    <entity charOffset="72-76" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e1" ontology_id="CHEBI_50906" text="role" type="chemical"/>
    <entity charOffset="217-225" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e2" ontology_id="CHEBI_36080" text="proteins" type="chemical"/>
    <entity charOffset="305-316" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e3" ontology_id="CHEBI_3638" text="Chloroquine" type="chemical"/>
    <entity charOffset="321-329" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e4" ontology_id="CHEBI_28938" text="Ammonium" type="chemical"/>
    <entity charOffset="321-338" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e5" ontology_id="CHEBI_31206" text="Ammonium chloride" type="chemical"/>
    <entity charOffset="330-338" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e6" ontology_id="CHEBI_17996" text="chloride" type="chemical"/>
    <entity charOffset="362-367" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e7" ontology_id="CHEBI_22695" text="bases" type="chemical"/>
    <entity charOffset="467-476" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e8" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="491-502" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e9" ontology_id="CHEBI_3638" text="Chloroquine" type="chemical"/>
    <entity charOffset="670-681" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e10" ontology_id="CHEBI_3638" text="Chloroquine" type="chemical"/>
    <entity charOffset="729-732" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e11" ontology_id="CHEBI_53233" text="MTT" type="chemical"/>
    <entity charOffset="763-772" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e12" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="786-797" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e13" ontology_id="CHEBI_3638" text="Chloroquine" type="chemical"/>
    <entity charOffset="928-939" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e14" ontology_id="CHEBI_3638" text="Chloroquine" type="chemical"/>
    <entity charOffset="1049-1060" id="bd0d94a4452f2b55cfab53adecb84ce5f2c91fe3.c1.e15" ontology_id="CHEBI_3638" text="Chloroquine" type="chemical"/>
  </chunk>
</document>
